|
Have you or someone you know been diagnosed with Chronic Myelogenous Leukemia (CML) and failed treatment with Gleevec® (imatinib mesylate), Sprycel® (dasatinib) or Tasigna® (nilotinib)?
Have you or someone you know been identified with the T315I mutation?
|
|
This website will allow you to find out more information about clinical trials that are being conducted by ChemGenex Pharmaceuticals and The Stragen Group for these CML patients.
|
|
Gleevec® is a registered trademark of Novartis AG.
Sprycel® is a registered trademark of Bristol-Myers Squibb Company.
Tasigna® is a registered trademark of Novartis AG.
|
|
